placebo Placebo: 37.2% M 3 mg: 28.8% M 10 mg: 24.4% PGI agonist Iloprost RR A02997 17 COMPOSITEd 12 weeks Improvement in NYHA class 16/09/2003 OR 3.97 (95% CI 1.47-10.75) placebo Baseline N. (%) Improved III Placebo: 59 (57.8) I: 60 (59.4) Placebo 12.7% IV Iloprost: 24.8% Placebo: 43 (42.2) I: 41 (40.6) 10% improvement in 6MWD Baseline, Mean±SD Improved I: 332±93 m 37.6% Placebo: 315±96 m 25.5% Selexipag GRIPHON21 COMPOSITEe Mean placebo: Complication related to PAH HR:0.60 (99% CI 0.46-0.78) 63.7 weeks placebo 12/05/2016 Hospitalization for worsening of PAH Mean selexipag: Placebo: 18.7% 70.6 weeks S: 13.6% Disease progression Placebo: 17.2% S: 6.6% PDE5 inhibitor Sildenafil A148114022 6MWD b 12 weeks Baseline, Mean±SD Mean change from 28/10/2005 20 mg: 38 m (99% CI: 12-64) baseline compared to 40 mg: 45 m (99% CI: 21-70) placebo (99% CI) placebo 80 mg: 42 m (99% CI: 9-75) Placebo: 344±79 - S 20 mg: 347±90 38 m (12-64) S 40 mg: 345±77 45 m (21-70) S 80 mg: 339±79 42 m (9-75) Tadalafil 6MWD b Baseline, Mean±SD Baseline, Mean±SD Δ
placebo Placebo: 37.2% M 3 mg: 28.8% M 10 mg: 24.4% PGI agonist Iloprost 16/09/2003 RR A02997 17 placebo COMPOSITEd OR 3.97 (95% CI 1.47-10.75) Improvement in NYHA class 12 weeks Baseline N. (%) Improved III Placebo: 59 (57.8) I: 60 (59.4) Placebo 12.7% Iloprost: 24.8% IV Placebo: 43 (42.2) I: 41 (40.6) 10% improvement in 6MWD Baseline, Mean±SD Improved I: 332±93 m 37.6% Placebo: 315±96 m 25.5% Selexipag 12/05/2016 GRIPHON21 placebo COMPOSITEe HR:0.60 (99% CI 0.46-0.78) Complication related to PAH Mean placebo: 63.7 weeks Mean selexipag: 70.6 weeks Hospitalization for worsening of PAH Placebo: 18.7% S: 13.6% Disease progression Placebo: 17.2% S: 6.6% PDE5 inhibitor Sildenafil 28/10/2005 A148114022 placebo 6MWD b 20 mg: 38 m (99% CI: 12-64) 40 mg: 45 m (99% CI: 21-70) 80 mg: 42 m (99% CI: 9-75) Baseline, Mean±SD Mean change from baseline compared to placebo (99% CI) 12 weeks Placebo: 344±79 - S 20 mg: 347±90 38 m (12-64) S 40 mg: 345±77 45 m (21-70) S 80 mg: 339±79 42 m (9-75) Tadalafil 6MWD b Baseline, Mean±SD Δ Baseline, Mean±SD
1-s2.0-S0953620518302000-mmc1.docx